415 related articles for article (PubMed ID: 26045239)
1. Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis.
Wan KH; Chen LJ; Young AL
Ocul Surf; 2015 Jul; 13(3):213-25. PubMed ID: 26045239
[TBL] [Abstract][Full Text] [Related]
2. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis.
Zhou XQ; Wei RL
Cornea; 2014 Jul; 33(7):760-7. PubMed ID: 24815112
[TBL] [Abstract][Full Text] [Related]
3. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
[TBL] [Abstract][Full Text] [Related]
5. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
Kim EC; Choi JS; Joo CK
Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
7. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
[TBL] [Abstract][Full Text] [Related]
8. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
9. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M
Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245
[No Abstract] [Full Text] [Related]
10. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
[TBL] [Abstract][Full Text] [Related]
11. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
12. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
13. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
14. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
[TBL] [Abstract][Full Text] [Related]
17. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
Schneider E; Paulsen F; Jacobi C
Klin Monbl Augenheilkd; 2020 May; 237(5):669-674. PubMed ID: 32434251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
